Review
Biochemistry & Molecular Biology
Morteza Abyadeh, Vivek Gupta, Joao A. Paulo, Veer Gupta, Nitin Chitranshi, Angela Godinez, Danit Saks, Mafruha Hasan, Ardeshir Amirkhani, Matthew McKay, Ghasem H. Salekdeh, Paul A. Haynes, Stuart L. Graham, Mehdi Mirzaei
Summary: This review discusses the therapeutic properties of cannabinoids found in cannabis for various diseases and the need for more research to understand the molecular and biochemical effects of cannabis at a cellular level. Proteomics technology is highlighted as an efficient tool to study the mechanistic effects of cannabis on the human body, drawing conclusions about its toxicity, therapeutic benefits, safety, and efficacy profiles.
Article
Pharmacology & Pharmacy
Sarah S. Stith, Xiaoxue Li, Franco Brockelman, Keenan Keeling, Branden Hall, Jacob M. Vigil
Summary: This study measured the associations between feeling high and treatment outcomes during cannabis consumption. The results showed that feeling high was associated with symptom relief but increased negative side effects. Factors such as plant phenotype, consumption mode, THC and CBD potencies, and dose influenced the intensity of feeling high for individual patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Sarah D. Pennypacker, Katharine Cunnane, Mary Catherine Cash, E. Alfonso Romero-Sandoval
Summary: Based on the analysis of online herbal dispensary products from nine U.S. states, it was found that most medical and recreational cannabis products may have THC:CBD ratios capable of causing significant acute intoxication, and this holds true across states with differing market policies. Patients seeking therapeutic benefits from cannabis products are at risk of unwanted side effects regardless of whether they obtain products from medical or recreational programs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Plant Sciences
Christopher J. Grassa, George D. Weiblen, Jonathan P. Wenger, Clemon Dabney, Shane G. Poplawski, S. Timothy Motley, Todd P. Michael, C. J. Schwartz
Summary: The study found that CBD-type cannabis primarily expresses cannabidiolic acid synthase (CBDAS), while cannabis strains with a balanced THC:CBD ratio express both CBDAS and THCAS. Cannabinoid synthase genes are arranged in tandem structure and embedded within long terminal repeat retrotransposons on chromosome 7.
Review
Food Science & Technology
Aurash J. Soroosh, Robin Henderson, Lori Dodson, Clifford S. Mitchell, Jed W. Fahey
Summary: Edible cannabis products (ECPs) made with food ingredients are vulnerable to contamination and pose potential health risks to consumers. Preventing accidental ingestion of ECPs is a major concern for public health professionals, who can benefit from adopting best practices and safety measures from the regulatory landscape in the United States to safeguard public health.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2021)
Article
Pharmacology & Pharmacy
Albert Garcia-Romeu, Joshua Elmore, Rhiannon E. Mayhugh, Nicolas J. Schlienz, Erin L. Martin, Justin C. Strickland, Marcel Bonn-Miller, Heather Jackson, Ryan Vandrey
Summary: Medicinal cannabis users perceive benefits from cannabis use for various conditions where traditional treatments are ineffective or unacceptable. However, concerns about cannabis side effects, legality, lack of information, and cost exist. More research and education on the safety and efficacy of medicinal cannabis/cannabinoid use are warranted.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Plant Sciences
Kenneth J. Olejar, Sang-Hyuck Park
Summary: Cross-pollination in the cannabis industry has been a topic of concern, with fears that low THC hemp may become high in THC if pollinated by high THC cannabis. However, the article highlights that there are multiple factors that contribute to THC levels, debunking the misconception that cross-pollination alone leads to increased THC in hemp crops.
FRONTIERS IN PLANT SCIENCE
(2022)
Article
Biochemistry & Molecular Biology
Laurel P. Gibson, Hollis C. Karoly, Jarrod M. Ellingson, Jost Klawitter, Cristina Sempio, Julia E. Squeri, Angela D. Bryan, L. Cinnamon Bidwell, Kent E. Hutchison
Summary: This study examined the acute effects of three cannabis flower chemovars with different THC to CBD ratios, finding that individuals using CBD-dominant or THC + CBD chemovars had lower plasma THC concentrations and reported less paranoia and anxiety compared to those using THC-dominant chemovar, while still experiencing similar positive mood effects. Further research is needed to clarify the potential harm reduction of CBD in cannabis products.
Article
Neurosciences
Amir Englund, Dominic Oliver, Edward Chesney, Lucy Chester, Jack Wilson, Simina Sovi, Andrea De Micheli, John Hodsoll, Paolo Fusar-Poli, John Strang, Robin M. Murray, Tom P. Freeman, Philip McGuire
Summary: As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful effects of cannabis use. This study aimed to determine if increasing the CBD content of cannabis can reduce its harmful effects. The results showed that increasing the CBD content did not reduce the harmful effects of cannabis on memory and psychotic symptoms. Therefore, CBD may not protect against the acute adverse effects of cannabis.
NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Brian L. Shaffer, Garrison M. Davis, Marc A. Incitti, Brian J. Piper, Brian Entler
Summary: A 63-year-old male with complex cardiac history presented with unstable angina which was not relieved by traditional medications but improved with medical cannabis treatment. This case suggests that medical cannabis may have a beneficial effect on angina symptoms and functional capacity in patients with coronary artery disease, warranting further investigation.
Article
Public, Environmental & Occupational Health
MaryBeth Dobbins, Mannat Rakkar, Katharine Cunnane, Sarah D. Pennypacker, Kimberly G. Wagoner, Beth A. Reboussin, E. Alfonso Romero-Sandoval
Summary: The U.S. legal cannabis market lacks distinction between medical and recreational programs, leading to the prevalence of high THC products. This poses risks to consumers, particularly patients, and suggests a potential influence of financial gain on the market composition.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Neurosciences
Markus Koestenberger, Gerhard Nahler, Trevor M. Jones, Stefan Neuwersch, Rudolf Likar
Summary: There is a growing interest in medical cannabis and cannabinoids treatments, with increasing research in the field. While medical cannabis plays a significant role in managing chronic pain, the existence of the entourage effect of other cannabis constituents remains controversial. CBD, a emerging cannabinoid, is gaining attention for its potential benefits, but further studies are needed to fully understand its effects.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
(2022)
Review
Clinical Neurology
Jimmy Li, Cassandra C. Areal, Denahin Hinnoutondji Toffa, Daphne Citherlet, Charles Deacon, Didier Jutras-Aswad, Mark Robert Keezer, Dang Khoa Nguyen
Summary: This scoping review summarized the literature on non-medical cannabis use in people with epilepsy (PWE), focusing on their experience, habits, and beliefs regarding non-medical cannabis. The majority of studies suggested that non-medical cannabis could aid in seizure control for PWE, but the research in this area is sparse and heterogeneous, and further research is needed to better understand PWE's experience, habits, and beliefs regarding non-medical cannabis.
FRONTIERS IN NEUROLOGY
(2023)
Review
Chemistry, Multidisciplinary
Akeemat O. Tijani, Divya Thakur, Dhruv Mishra, Dorcas Frempong, Umeh I. Chukwunyere, Ashana Puri
Summary: There is increasing legal acceptance of cannabis and cannabis-derived products for medicinal purposes in some countries, leading to renewed interest in research work related to cannabinoids. Clinical studies have demonstrated the therapeutic significance of cannabinoids, and efforts are being made to develop acceptable prescription products. However, drawbacks of conventional delivery forms of cannabinoids can be mitigated through transcutaneous drug delivery, which shows promise in developing effective delivery systems for cannabinoids.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Toxicology
Wiwit Suttithumsatid, Wanida Sukketsiri, Pharkphoom Panichayupakaranant
Summary: The study demonstrated that CBD, THC, and standardized cannabis extracts have significant inhibitory effects on the migration, invasion, and apoptosis of breast cancer cells, mainly through regulation of multiple signaling pathways. CBD showed particular effectiveness in inhibiting the mTOR pathway and inducing apoptosis.
TOXICOLOGY IN VITRO
(2023)
Article
Pharmacology & Pharmacy
Sarah D. Pennypacker, Katharine Cunnane, Mary Catherine Cash, E. Alfonso Romero-Sandoval
Summary: Based on the analysis of online herbal dispensary products from nine U.S. states, it was found that most medical and recreational cannabis products may have THC:CBD ratios capable of causing significant acute intoxication, and this holds true across states with differing market policies. Patients seeking therapeutic benefits from cannabis products are at risk of unwanted side effects regardless of whether they obtain products from medical or recreational programs.
FRONTIERS IN PHARMACOLOGY
(2022)